Neuren thinks big
Wednesday, 16 July, 2008
Neuren Pharmaceuticals [ASX: NEU] has concluded patient recruitment and dosing for its Phase III clinical trial of Glypromate, a therapeutic designed to reduce brain impairment after major heart surgery.
The recruitment of 320 patients has been concluded ahead of schedule, and Neuren is expecting to release provisional efficacy results before the end of the year.
Up to a third of patients suffer cognitive impairment three months after major heart surgery, and there is currently no approved treatment to prevent it.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
